APPLICATIONS PUBLISHED 14 JULY 2004
Published: 10-Jan-2005
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Binary compsn for 'prime boost' release of active ingredients like vaccines
Quadrant Drug Delivery 1435905*
Method for producing biologically active products
Schilling, Marvin 1435906*
Compsns and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
McNeil-PPC 1435907*
Oily paclitaxel compsn and formulation for chemoembolisation and preparation method thereof
Korea Institute of Science & Technology 1435908*
Stable compsn comprising particles in a frozen aqueous matrix
Baxter International 1435909*
Novel cyclosporin analogue micro-emulsion preconcentrates
Isotechnika 1435910*
Devices including protein matrix materials and methods using the same
Gel-Del Technologies 1435911*
Novel stable crystal form of N-trans-4-isopropylcyclohexyl carbonyl)-D-phenylalanine and process of preparation
Alembic 1435912*
Method of treating benign prostatic hyperplasia and other benign prostate conditions
Parks, L Dean 1435913*
Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides
Viscum 1435914*
Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
Apogepha Arzneimittel 1435915*
Powder processing with pressurised gaseous fluids
Boehringer Ingelheim Pharmaceuticals 1435916*
Solid pharmaceutical formulation for a piperazine urea derivative
Schering Aktiengesellschaft 1435917*
Highly compressible ethyl cellulose for tableting
Hercules 1435918*
Device and method for accurate delivery of an active agent
Durect 1435919*
Flow regulator
Durect 1435920*
Use of a multilayer controlled-release tablet comprising ropinirole for the manufacture of a medicament for the treatment of fibromylagia
SmithKline Beecham (Cork) 1435921*
Use if a copolymer to produce a galenic form containing a peptide or a protein as active agent
Roehm 1435922*
Methods and apparatus for improved administration of analgesics
Zars 1435923*
Therapeutic compsn and use
Barts and the London NHS Trust; Queen Mary & Westfield College 1435924*
Gap junctions and EDHF
University of Wales College of Medicine 1435925*
Method for the treatment and prevention of disturbances of the central nervous system associated with an alteration of glutamatergic neurotransmission by administration of 2-aminobenzenesulfonamide derivatives
RETT Corp 1435926*
Method for treating skin disorders
Johnson & Johnson 1435927*
Allicin
Stone Island Holdings 1435928*
Compsn comprising cysteamine for improving lactation in dairy animals
Walcom Animal Science 1435929*
Anti-glycation agents for preventing age-, diabetes- and smoking-related complications
National Research Council of Canada 1435930*
Dosage form for treatment of diabetes mellitus
Sun Pharmaceuticals 1435931*
Inhibitors of RNASE P proteins as antibacterial compounds
Message Pharmaceuticals 1435932*
5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435933*
5'-acylamino-1,1'-piphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435934*
Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions
Alliance Pharmaceutical 1435935*
5--carbamoyl-1,1-biphenyl-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435936*
Compsn comprising paracetamol and a bitterness masking component
Reckit Benckiser Healthcare (UK) 1435937*
Modulation of ocular growth and myopia by GABA drugs
The Trustees of the University of Pennsylvania 1435938*
Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins
Conforma Therapeutic Corp; Zhang, Lin 1435939*
Treatment of scleroderma
Cell Pathways 1435940*
Wortmannin analogues and methods of using same
Powis, Garth 1435941*
5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435942*
Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia
UCB 1435943*
4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as PDE-4 inhibitors for the treatment of neurological syndromes
Memory Pharmaceutical Corp 1435944*
Transdermal migraine therapy
Aung-din, Ronald 1435945*
Linked biaryl compounds
Tularik; Japan Tobacco 1435946*
2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as CDS1/CHK2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
Ortho-McNeil Pharmaceutical 1435947*
Aminoisoxazole derivatives active as kinase inhibitors
Pharmacia Italia 1435948*
2'-methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435949*
2'-methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors
Glaxo Group 1435950*
Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
Bayer Pharmaceuticals 1435951*
8-amino-1,2,4]triazolo 1,5-A]pyridine 6-carboxylic acid amide
F Hoffmann-La Roche 1435952*
Antivesicant compounds and methods of making and using thereof
US Army Medical Research and Materiel Command 1435953*
High purity amlodipine benzenesulphonate and a process for its preparation
Lek Pharmaceuticals and Chemical 1435954*
N-aroyl cyclic amine derivatives as orexin receptor antagonists
SmithKline Beecham 1435955*
Therapeutic combinations for cardiovascular and inflammatory indications
Pharmacia 1435956*
Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes
Vertex Pharmaceuticals 1435957*
Use of phosphodiesterase inhibitors
Merck Patent 1435958*
Inhibitors of the EGF receptor for the treatment of thyroid cancer
University of Cincinatti 1435959*
Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosines A2A receptor antagonsists
Schering 1435960*
Treatment for lupus erythematosus
Cell Pathways 1435961*
Reduced toxicity cisplatin formulations and methods for using the same
Tosk 1435963*
Novel prodrugs of N-H bond-containing compounds and methods of making thereof
The University of Kansas 1435964*
Pharmaceutical compsns and methods for treating cancer
Intermune 1435965*
Method for inhibiting the proliferation of hepatic stellate cells with a ligand of low affinity glucocorticoid binding site (LAGS)
The University Court of the University of Aberdeen 1435966*
Methods for preventing and treating bone loss with a steroid compounds
Pharmacia Italia; Pharmacia & Upjohn 1435967*
Combinations comprising COX-2 inhibitors and aspirin
Novartis 1435968*
Method of modulating sodium ion absorption on epithelial cells
Inologic 1435969*
Methods of treating skin with diphosphonate derivatives
Ilex Products 1435970*
Utilisation of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)
Bioghurt Biogarde 1435971*
Novel synthetic ganglioside derivatives and compsns thereof
Neose Technologies 1435972*
Co-administration of transport protein with conjugated cobalamin to deliver agents
Mayo Foundation for Medical Education and Research 1435973*
Methods and compsns ror treating hepatitis C virus using 4'-modified nucleosides
Idenix (Cayman); Centre National de la Recherche Scientifique; L'Universite Montpellier II 1435974*
Methods of using 279, a human G protein-coupled receptor
Millennium Pharmaceuticals 1435975*
Pharmaceutical compsn comprising chito-oligomers
Primex EHF 1435976*
Cardiac transplantation of stem cells for the treatment of heart failure
Henry Ford Health System 1435977*
Esters of aromatic alkoxylated alcohols and fatty carboxylic acids
Croda 1435978*
Methods for treating multiple sclerosis
Chiron Corp 1435979*
Stratified cartilage tissue and methods to engineer same
Rush-Presbyterian-St Luke's Medical Centre; University of California, San Diego 1435980*
Anti-tumour activity from reptile serum
Natural Cure 1435981*
Delivery system for pharmaceutical, nutrition and cosmetic ingredients
Natreon; Indian Herbs Research & Supply 1435982*
Concentrate comprising green tea, grape skin extract and grape seed extract, the production thereof and the use of the same
Rudolf Wild 1435933*
Use of histamine to treat liver disease
Maxim Pharmaceuticals 1435934*
Medicament containing activated antithrombin III
Kehrel, Beate 1435985*
IGF-binding protein-derived peptide or small molecule
Bioexpertise 1435986*
Method and compsn for treating immune complex associated disorders
The Trustees of Boston University 1435987*
Improved use of antitumoural compound in cancer therapy
Pharmamar 1435988*
TP1B inhibitors and ligands
Albert Einstein College of Medicine of Yeshiva University 1435989*
Kahalide compounds for use in cancer therapy
Pharma Mar 1435990*
Use of alpidine for the treatment of pancreatic cancer
Pharma Mar 1435991*
Chemokines as adjuvants of immune responses
Schering 1435992*
Novel use of pulmonary surfactant
Altana Pharma 1435994*
Compsn and method for treating diabetes
GMP Endotherapeutics 1435995*
Compns comprising mixtures of therapeutic proteins and methods of producing the same
Genetrol Biotherapeutics 1435996*
Method for treating hepatitis C virus infection in treatment failure patients
Intermune 1435997*
Method for treating hepatitis C virus infection in treatment failure patients
Intermune 1435998*
Additive cytoprotective effects of two bioactive regions of pro-optiomelanocortin hormone
Ademovic, Zlatko; Konjevoda, Pasko; Mikus, Darko 1435999*
Treatment of non-solid mammalian tumours with vascular endothelial growth factor receptor antagonists
Imclone Systems 1436000*
Inhibition of neonatal hyperbilirubinemia in breast-fed infants
Wisconsin Alumni Research Foundation 1436005*
Viral inhibition by N-docosanol
Avanir Pharmaceuticals 1436006*
Compounds for use as surfactants
Glaxo Group 1436007*
Controlled release drug delivery compsn comprising polycationic polymer and negatively charged pharmacologically active compound
The University of British Columbia; Arc Pharmaceuticals 1436008*
Pharmaceutical formulation
AstraZeneca 1436009*
Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compsns and methods
3M Innovative Properties 1436010*
Dandrimers for use in targeted delivery
University of Strathclyde; The University Court of the University of Glasgow 1436011*
Polymer conjugates of opioid antagonists
Nektar Therapeutics 1436012*
